Melatonin is a hormone found naturally in the body. Melatonin's main job is to regulate night and day cycles also known as sleep-wake cycles. Darkness causes the body to produce more melatonin, which signals the body to prepare for sleep; while light decreases melatonin production and signals the body to prepare for being awake. Some people who have trouble sleeping have low levels of melatonin.
Sleep EZ is a special formulation of melatonin. Most companies use synthetic melatonin produced in the lab, commonly available in pill form. This is an ineffective form of melatonin. It is poorly absorbed by the body and the dosage cannot be adjusted accurately.
Sleep EZ is a convenient liquid form that’s been cultured with beneficial probiotic organisms for active and increased bioavailability. This formula is not animal derived, so it is suitable for vegetarians and vegans.
BENEFITS
- Non-Habit Forming
- Promotes Restful Sleep
- Relieves Jet Lag
- Dosage can be controlled
NON-GMO
NO Gluten, Yeast, Milk, Lactose, Soy, Artificial Flavors, Sweeteners, Preservatives
Uses
Trouble falling asleep at a conventional bedtime (delayed sleep-wake phase disorder-DSWPD). Taking melatonin by mouth appears to reduce the length of time needed to fall asleep in young adults and children who have trouble falling asleep.
Non-24-hour sleep wake disorder. Taking melatonin at bedtime can improve sleep in children and adults who are blind.
Sleep disturbance caused by certain blood pressure medicine (beta blocker-induced insomnia). Beta-blocker drugs, such as atenolol/Tenormin, carvedilol/Coreg, metoprolol/Lopressor and propranolol/Inderal, can lower melatonin levels resulting in sleep problems. Research shows that taking a melatonin supplement might reduce problems sleeping in patients taking beta-blocker drugs.
Jet lag. Most research shows that melatonin can improve fatigue and daytime sleepiness associated with jet lag. It can also improve alertness and movement coordination. Melatonin has been shown to help you quickly acclimate to time zone changes that may interfere with your ability to fall asleep.
Anxiety before surgery. Melatonin used under the tongue seems to be as effective at reducing anxiety before surgery as midazolam, a conventional medication.
Serving Size
1 full dropper (1 mL)............................8 mg Melatonin
Servings per container
54
Active Ingredient:
Melatonin1
Other ingredients:
Purified Water, Organic Cane (non-GMO) Alcohol, Organic Molasses.
1Fermented in a probiotic culture which is inactivated after fermentation; preserved with organic cane (non-GMO) alcohol.
Numerous studies have validated the effectiveness of Melatonin.
MELATONIN CLINICAL STUDIES
Show
Hide
Clinical uses of melatonin: evaluation of human trials.
Curr Med Chem. 2010;17(19):2070-95.
Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ.
Abstract
During the last 20 years, numerous clinical trials have examined the therapeutic usefulness of melatonin in different fields of medicine. The objective of this article is to review, in depth, the science regarding clinical trials performed to date. The efficacy of melatonin has been assessed as a treatment of ocular diseases, blood diseases, gastrointestinal tract diseases, cardiovascular diseases, diabetes, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, infectious diseases, neurological diseases, sleep disturbances, aging and depression. Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care. The conclusion of the current review is that the use of melatonin as an adjuvant therapy seems to be well funded for macular degeneration, glaucoma, protection of the gastric mucosa, irritable bowel syndrome, arterial hypertension, diabetes, side effects of chemotherapy and radiation in cancer patients or hemodialysis in patients with renal insufficiency and, especially, for sleep disorders of circadian etiology (jet lag, delayed sleep phase syndrome, sleep deterioration associated with aging, etc.) as well as in those related with neurological degenerative diseases (Alzheimer, etc.,) or Smith-Magenis syndrome. The utility of melatonin in anesthetic procedures has been also confirmed. More clinical studies are required to clarify whether, as the preliminary data suggest, melatonin is useful for treatment of fibromyalgia, chronic fatigue syndrome, infectious diseases, neoplasias or neonatal care. Preliminary data regarding the utility of melatonin in the treatment of ulcerative colitis, Crohn's disease, rheumatoid arthritis are either ambiguous or negative. Although in a few cases melatonin seems to aggravate some conditions, the vast majority of studies document the very low toxicity of melatonin over a wide range of doses.
Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders.
Sleep Med Rev. 2017 Aug;34:10-22. doi: 10.1016/j.smrv.2016.06.005. Epub 2016 Jul 20.
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL.
Abstract
Melatonin is a physiological hormone involved in sleep timing and is currently used exogenously in the treatment of primary and secondary sleep disorders with empirical evidence of efficacy, but very little evidence from randomised, controlled studies. The aim of this meta-analysis was to assess the evidence base for the therapeutic effects of exogenous melatonin in treating primary sleep disorders. An electronic literature review search of MEDLINE (1950-present) Embase (1980- present), PsycINFO (1987- present), and Scopus (1990- present), along with a hand-searching of key journals was performed in July 2013 and then again in May 2015. This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, non 24-h sleep wake syndrome in people who are blind, and rapid eye movement-behaviour disorder. Meta-analyses were performed to determine the magnitude of effect in studies of melatonin in improving sleep. A total of 5030 studies were identified; of these citations, 12 were included for review based on the inclusion criteria of being: double or single-blind, randomised and controlled. Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia (p = 0.002), delayed sleep phase syndrome (p < 0.0001), and regulating the sleep-wake patterns in blind patients compared with placebo. These findings highlight the potential importance of melatonin in treating certain first degree sleep disorders. The development of large-scale, randomised, controlled trials is recommended to provide further evidence for therapeutic use of melatonin in a variety of sleep difficulties.
Efficacy of melatonin Sleep-Wake Phase Disorder
PLOS Medicine - June 18, 2018 - https://doi.org/10.1371/journal.pmed.1002587
Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial
Tracey L. Sletten , Michelle Magee, Jade M. Murray, Christopher J. Gordon, Nicole Lovato, David J. Kennaway, Stella M. Gwini, Delwyn J. Bartlett, Steven W. Lockley, Leon C. Lack, Ronald R. Grunstein, Shantha M. W. Rajaratnam, for the Delayed Sleep on Melatonin (DelSoM) Study Group
Abstract
BACKGROUND:
Delayed Sleep-Wake Phase Disorder (DSWPD) is characterised by sleep initiation insomnia when attempting sleep at conventional times and difficulty waking at the required time for daytime commitments. Although there are published therapeutic guidelines for the administration of melatonin for DSWPD, to our knowledge, randomised controlled trials are lacking. This trial tested the efficacy of 0.5 mg melatonin, combined with behavioural sleep-wake scheduling, for improving sleep initiation in clinically diagnosed DSWPD patients with a delayed endogenous melatonin rhythm relative to patient-desired (or -required) bedtime (DBT).
CONCLUSIONS:
In this study, melatonin treatment 1 h prior to DBT combined with behavioural sleep-wake scheduling was efficacious for improving objective and subjective measures of sleep disturbances and sleep-related impairments in DSWPD patients with delayed circadian phase relative to DBT. Improvements were achieved largely through the sleep-promoting effects of melatonin, combined with behavioural sleep-wake scheduling.
Melatonin for pre‐ and postoperative anxiety in adults
Cochrane Database Syst Rev. 2015 Apr; 2015(4): CD009861
Melissa V Hansen,corresponding author Natalie L Halladin, Jacob Rosenberg, Ismail Gögenur, and Ann Merete Møller
Abstract
BACKGROUND:
Anxiety in relation to surgery is a well-known problem. Melatonin offers an atoxic alternative to benzodiazepines in ameliorating this condition in the pre- and postoperative period.
CONCLUSIONS:
Melatonin compared to placebo, given as premedication (tablets or under the tongue (sublingually)) reduced preoperative anxiety (measured 50 to 100 minutes after administration). Melatonin may be equally as effective as standard treatment with midazolam in reducing preoperative anxiety (measured 50 to 100 minutes after administration). When compared to placebo, melatonin may reduce postoperative anxiety (six hours after surgery).
Suggested Use
Shake gently before each use.
Take 1 full dropper just before sleep, or as directed by a health professional.
Hold solution under tongue for 15 seconds before swallowing.
Note:
A full dropper is equivalent to 8 mg of melatonin. If you experience excessive vivid dreams throughout the night, you can decrease the dosages. Some people do fine with just a couple of drops of melatonin. You may adjust the dosage based on what’s right for you.
Sleep EZ is formulated to help you fall asleep for those who have difficulty drifting off at bedtime. This formulation is not intended to keep you asleep throughout the night. If you wake in the middle of the night, you should take Sleepy Time formula along with Sleep EZ.
